$EBS (Emergent BioSolutions, Inc.)

$EBS {{ '2016-04-15T22:16:09+0000' | timeago}} • Announcement

$EBS said that it had done the initial filing of Form 10 with SEC with respect to the previously planned spin-off of certain assets of its biosciences business to create a separate, publicly-traded company, Aptevo Therapeutics Inc. The spin-off is expected to complete in mid-2016.

$EBS {{ '2018-01-08T14:21:21+0000' | timeago}} • Announcement

$EBS expects total revenues to be $715-755MM for full-year 2018. Net income is expected to be $95-110MM while adjusted net income is expected to be $110-125MM. Pretax income is expected to be $120-140MM while EBITDA is expected to be $175-190MM for full-year 2018.

$EBS {{ '2018-01-08T14:21:06+0000' | timeago}} • Announcement

$EBS announced preliminary 2017 financial results. For full-year 2017, $EBS expects total revenue of $555-560MM and BioThrax sales of approx. $286MM. $EBS expects net income to be $80-84MM and adjusted net income to be $92-96MM. Cash and cash equivalents at 2017-end are expected to be approx. $180MM.

$EBS {{ '2017-11-20T13:13:07+0000' | timeago}} • Announcement

$EBS said that the US FDA has approved the sBLA for the manufacture of ACAM2000 in the company’s newly-acquired cGMP live viral manufacturing facility in Canton, Massachusetts. ACAM2000 is the only FDA-licensed vaccine for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.

$EBS {{ '2017-10-06T16:07:34+0000' | timeago}} • Announcement

$EBS completed its acquisition of Sanofi’s ACAM2000 (Smallpox Vaccine, Live) business, which includes ACAM2000, cGMP live viral manufacturing facility and office and warehouse space, both in Canton, Massachusetts, and a cGMP viral fill/finish facility in Rockville, Maryland.

$EBS {{ '2017-10-04T12:11:30+0000' | timeago}} • Announcement

$EBS has been awarded a contract valued at up to approximately $25MM by the U.S. Department of State to supply TROBIGARD auto-injector, a drug and device combination product for emergency use in the event of nerve agent or organophosphate poisoning.

$EBS {{ '2017-10-03T13:27:49+0000' | timeago}} • Announcement

Life sciences firm $EBS completed the acquisition of raxibacumab, an FDA-approved human monoclonal antibody for the treatment of inhalational anthrax, from $GSK. The company plans a $130MM contract with the Biomedical Advanced Research and Development Authority to supply the product to the US Strategic National Stockpile through November 2019.

$EBS {{ '2017-10-02T11:57:04+0000' | timeago}} • Announcement

Life sciences company $EBS said it has completed a $200MM syndicated senior secured credit facility. The new five-year facility replaces the company’s previous $100MM facility that was scheduled to expire in December 2018. The new facility enhances Emergent’s financial flexibility by increasing the capacity to drive growth through acquisitions.

$EBS {{ '2017-09-25T11:45:12+0000' | timeago}} • Announcement

$EBS received a 5-year follow-on contract valued at up to about $171MM from the U.S. Department of Defense (DoD) to supply RSDL (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military. The RSDL Kit is intended to remove or neutralize chemical warfare agents and T-2 toxin from the skin.

$EBS {{ '2017-07-28T14:11:37+0000' | timeago}} • Announcement

$EBS and Valneva plan to initiate the Phase 1 trial in late 2017 or early 2018 and will share all costs until the availability of Phase 1 data, which is expected within six months from trial initiation. $EBS will have option to continue development arrangement with Valneva for milestone payment of EUR5MM, upon availability of Phase 1 data.

$EBS {{ '2017-07-28T14:10:27+0000' | timeago}} • Announcement

$EBS will pay Valneva EUR1MM upfront and will get exclusive rights to use Valneva’s intellectual property and know-how related to Zika product development. The companies are expected to enter into a technology transfer agreement at a later time to enable transfer of Valneva's technology to $EBS' Bayview manufacturing facility in Baltimore, MD.

$EBS {{ '2017-07-28T13:58:39+0000' | timeago}} • Announcement

$EBS announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's Zika vaccine technology, ZIKV. Emergent and Valneva will co-develop ZIKV-VLA1601, a highly purified inactivated vaccine candidate against Zika virus, from preclinical development through completion of a Phase 1 safety and immunogenicity clinical trial.

$EBS {{ '2017-07-14T12:28:37+0000' | timeago}} • Announcement

$EBS has entered into an agreement to acquire the ACAM2000 business of Sanofi in an all-cash transaction with a total value of $125MM. The transaction, which is subject to customary closing conditions including antitrust regulatory approval, is expected to close in 2017.

$EBS {{ '2017-05-31T13:56:24+0000' | timeago}} • Announcement

$EBS has signed a modification to its contract with the Biomedical Advanced Research and Development Authority to produce and store bulk drug substance for its botulism antitoxin (BAT). The value of the deal is $53MM, with a 5-year performance period. BAT is indicated for treatment of symptomatic botulism following exposure to botulinum neurotoxin.

$EBS {{ '2017-03-31T12:52:41+0000' | timeago}} • Announcement

$EBS signed a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) to manufacture and store bulk drug substance for its botulism antitoxin, BAT (Botulism Antitoxin Heptavalent), valued at about $53MM with a 5-year period of performance.

$EBS {{ '2017-02-13T13:12:00+0000' | timeago}} • Announcement

$EBS received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $30.5MM to develop monoclonal antibody therapeutics for viral hemorrhagic fever. This task order will utilize $EBS' Center for Innovation in Advanced Development and Manufacturing (CIADM) facility located in Baltimore, Maryland.

$EBS {{ '2017-02-01T14:32:53+0000' | timeago}} • Announcement

$EBS initiated a Phase 1b multiple ascending dose study to evaluate safety and tolerability of UV-4B, its novel antiviral candidate being developed as potential oral treatment for dengue viral infection. This study, which will enroll 40 healthy adults in U.S. sites, follows successful Phase 1a single ascending dose clinical study completed in 2016.

$EBS {{ '2016-12-12T13:49:07+0000' | timeago}} • Announcement

$EBS reported that Health Canada has approved the company’s New Drug Submission for BAT, a drug for treating a potentially fatal disease. The company has an existing ten-year contract, executed in 2012, to supply BAT to the Canadian Department of National Defense, the Public Health Agency of Canada and individual provincial health authorities.

$EBS {{ '2016-12-09T12:40:11+0000' | timeago}} • Announcement

On continuing operations basis, $EBS now expects 2016 total revenue of $465-485MM, BioThrax sales of $220-235MM, net income of $50-60MM and adjusted net income of $65-75MM. On a combined basis, $EBS now expects 2016 total revenue of $485-505MM, net income of $35-45MM and adjusted net income of $55-65MM.

$EBS {{ '2016-12-09T12:37:52+0000' | timeago}} • Announcement

$EBS signed follow-on contract with CDC valued at up to $911MM to supply to the Strategic National Stockpile (SNS) about 29.4MM doses of BioThrax through September 2021. BARDA issues notice of intent to separately procure about $100MM of BioThrax for SNS over 24 months from contract award, which is expected in 1H17

$EBS {{ '2016-12-09T12:36:33+0000' | timeago}} • Announcement

$EBS said U.S. Department of Health and Human Services is advancing its anthrax preparedness strategy with multiple contract actions for $EBS' anthrax vaccines. $EBS signed follow-on contract with the Centers for Disease Control and Prevention.

Recent Transcripts

VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
NKTR (Nektar Therapeutics)
Tuesday, November 7 2017 - 10:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
EBS (Emergent BioSolutions, Inc.)
Thursday, November 2 2017 - 9:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
INCY (Incyte Corporation)
Tuesday, October 31 2017 - 2:00pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, October 26 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, October 26 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, October 25 2017 - 8:30pm
GSK (GlaxoSmithKline plc)
Wednesday, October 25 2017 - 1:00pm
NVS (Novartis AG)
Tuesday, October 24 2017 - 12:00pm
ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Wednesday, August 9 2017 - 8:30pm

AlphaGraphics you may like